» Articles » PMID: 21993441

Role of Flow Cytometry Immunophenotyping in the Diagnosis of Leptomeningeal Carcinomatosis

Abstract

Purpose: To explore the contribution of flow cytometry immunophenotyping (FCI) in detecting leptomeningeal disease in patients with solid tumors.

Experimental Design: Cerebrospinal fluid (CSF) samples from 78 patients who received a diagnosis of epithelial-cell solid tumors and had clinical data suggestive of leptomeningeal carcinomatosis (LC) were studied. A novel FCI protocol was used to identify cells expressing the epithelial cell antigen EpCAM and their DNA content. Accompanying inflammatory cells were also described. FCI results (positive or negative for malignancy) were compared with those from CSF cytology and with the diagnosis established by the clinicians: patients with LC (n = 49), without LC (n = 26), and undetermined (n = 3).

Results: FCI described a wide range of EpCAM-positive cells with a hyperdiploid DNA content in the CSF of patients with LC. Compared with cytology, FCI showed higher sensitivity (75.5 vs 65.3) and negative predictive value (67.6 vs 60.5), and similar specificity (96.1 vs 100) and positive predictive value (97.4 vs 100). Concordance between cytology and FCI was high (Kp = 0.83), although misdiagnosis of LC did not show differences between evaluating the CSF with 1 or 2 techniques (P = .06). Receiver-operator characteristic curve analyses showed that lymphocytes and monocytes had a different distribution between patients with and without LC.

Conclusion: FCI seems to be a promising new tool for improving the diagnostic examination of patients with suspicion of LC. Detection of epithelial cells with a higher DNA content is highly specific of LC, but evaluation of the nonepithelial cell compartment of the CSF might also be useful for supporting this diagnosis.

Citing Articles

Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease.

Zhu J, Shum M, Qazi M, Sahgal A, Das S, Dankner M J Neurooncol. 2024; 172(1):31-40.

PMID: 39704899 DOI: 10.1007/s11060-024-04902-0.


The path to leptomeningeal metastasis.

Remsik J, Boire A Nat Rev Cancer. 2024; 24(7):448-460.

PMID: 38871881 PMC: 11404355. DOI: 10.1038/s41568-024-00700-y.


New Breakthroughs in the Diagnosis of Leptomeningeal Carcinomatosis: A Review of Liquid Biopsies of Cerebrospinal Fluid.

Goldberg M, Mondragon-Soto M, Altawalbeh G, Meyer B, Aftahy A Cureus. 2024; 16(2):e55187.

PMID: 38558729 PMC: 10980855. DOI: 10.7759/cureus.55187.


Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors.

Diaz M, Chudsky S, Pentsova E, Miller A Transl Oncol. 2024; 41:101881.

PMID: 38218027 PMC: 10825768. DOI: 10.1016/j.tranon.2024.101881.


Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.

Steininger J, Gellrich F, Engellandt K, Meinhardt M, Westphal D, Beissert S Int J Mol Sci. 2023; 24(14).

PMID: 37511202 PMC: 10380419. DOI: 10.3390/ijms241411443.


References
1.
Darzynkiewicz Z, Halicka H, Zhao H . Analysis of cellular DNA content by flow and laser scanning cytometry. Adv Exp Med Biol. 2010; 676:137-47. PMC: 2967208. DOI: 10.1007/978-1-4419-6199-0_9. View

2.
Liu J, Jia H, Yang Y, Dai W, Su X, Zhao G . Cerebrospinal fluid cytology and clinical analysis of 34 cases with leptomeningeal carcinomatosis. J Int Med Res. 2010; 37(6):1913-20. DOI: 10.1177/147323000903700629. View

3.
Quijano S, Lopez A, Sancho J, Panizo C, Deben G, Castilla C . Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009; 27(9):1462-9. DOI: 10.1200/JCO.2008.17.7089. View

4.
Nagrath S, Sequist L, Maheswaran S, Bell D, Irimia D, Ulkus L . Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450(7173):1235-9. PMC: 3090667. DOI: 10.1038/nature06385. View

5.
Leers M, Schoffelen R, Hoop J, Theunissen P, Oosterhuis J, vd Bijl H . Multiparameter flow cytometry as a tool for the detection of micrometastatic tumour cells in the sentinel lymph node procedure of patients with breast cancer. J Clin Pathol. 2002; 55(5):359-66. PMC: 1769646. DOI: 10.1136/jcp.55.5.359. View